The objective of this application is to establish the CORE Leadership Group and a Network Laboratory for the Microbicide Trials Network (MTN). The objective of the Leadership Group is to provide oversight and coordination of a portfolio of clinical trials on topical microbicides for prevention of HIV. The mission of the Microbicide Trials Network is to reduce the sexual transmission of HIV through the development and evaluation of products which reduce the transmission of HIV when applied topically to mucosal surfaces. The goal is to conduct scientifically rigorous and ethically sound clinical trials of microbicide safety and effectiveness which will support licensure of these products. The MTN CORE and Network Laboratory will be headquartered in Pittsburgh under the direction of Dr. Sharon Hillier (CORE) and Dr. Charlene Dezzutti (Network Laboratory). CORE support for the MTN will be coordinated through Pittsburgh in collaboration with investigators at the University of Washington in Seattle and UCLA in Los Angeles, as well as Family Health International, in Raleigh North Carolina. The Network Laboratory is composed of a Comparative Assessment Core, a Site Support and Diagnostic Testing Core, a Virology Gore, a Pharmacology Core, and a Immunology Core. The MTN proposes a portfolio of 15 new clinical trials which span early safety to effectiveness studies. In addition, the MTN will assume direction for two ongoing microbicide studies which were developed under the HPTN, HPTN 035 and 059. Clinical trial sites will be located in the US and in Africa. The MTN will collaborate with other DAIDS sponsored networks and groups engaged in microbicide research internationally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
3UM1AI068633-07S1
Application #
8627237
Study Section
Special Emphasis Panel (ZAI1-ML-A (J1))
Program Officer
Black, Roberta J
Project Start
2006-06-29
Project End
2013-12-31
Budget Start
2013-06-01
Budget End
2013-12-31
Support Year
7
Fiscal Year
2013
Total Cost
$8,254,853
Indirect Cost
$1,618,849
Name
Magee-Women's Research Institute and Foundation
Department
Type
DUNS #
119132785
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Abbai, Nathlee S; Nyirenda, Makandwe; Naidoo, Sarita et al. (2018) Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa. AIDS Behav 22:2172-2180
Laborde, Nicole D; Pleasants, Elizabeth; Reddy, Krishnaveni et al. (2018) Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex. AIDS Behav 22:437-446
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411
Justman, Jessica E; Nair, Gonasagrie Lulu; Hendrix, Craig W et al. (2018) Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. J Acquir Immune Defic Syndr 78:175-182
Mhlanga, Felix G; Noguchi, Lisa; Balkus, Jennifer E et al. (2018) Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials. HIV Clin Trials 19:8-14
Balkus, Jennifer E; Brown, Elizabeth R; Palanee-Phillips, Thesla et al. (2018) Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring. J Acquir Immune Defic Syndr 77:e8-e10
Musara, Petina; Montgomery, Elizabeth T; Mgodi, Nyaradzo M et al. (2018) How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe. AIDS Behav 22:877-886
Montgomery, Elizabeth T; Stadler, Jonathan; Naidoo, Sarita et al. (2018) Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results. AIDS 32:1517-1525
Makanani, Bonus; Balkus, Jennifer E; Jiao, Yuqing et al. (2018) Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy. J Acquir Immune Defic Syndr 79:566-572
Balán, Iván C; Giguere, Rebecca; Brown 3rd, William et al. (2018) Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017. AIDS Behav 22:986-995

Showing the most recent 10 out of 113 publications